Bitcoin surges above $70K as Trump backs Clarity Act, Treasury ramps up buybacks
Bitcoin jumped 4.6% to $72,475.25 – a roughly 12% gain over the past two days after the digital asset was trading near $63,000 earlier this week.
FOLD - Amicus Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.86
DETAILS
HIGH:
$19.00
LOW:
$13.00
MEDIAN:
$14.50
CONSENSUS:
$14.86
UPSIDE:
2.55%
Stock News
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition
BioMarin Pharmaceutical remains a "Strong Buy," driven by pipeline progress, strategic acquisitions, and robust revenue guidance. BMRN's acquisition of Amicus Therapeutics adds GALAFOLD and POMBILITI + OPFOLDA, boosting 2026 revenue guidance to $3.825–$3.925 billion and targeting 20% YoY growth. VOXZOGO expansion into hypochondroplasia and ongoing clinical trials represent major catalysts, with topline Phase 3 data expected in Q2 2026.
CIBRA Capital Makes a Big Merger Arbitrage Bet On Amicus Therapeutics (FOLD)
Amicus Therapeutics targets rare genetic diseases with proprietary therapies and a pipeline of treatments for underserved patient groups.
BioMarin Pharmaceutical's Rare Disease Portfolio Supplemented By Amicus Acquisition Makes A Buy
BioMarin (BMRN) has declined over 12% since January 2025, despite prior optimism. The investment thesis centers on the potential of VOXZOGO and Amicus's two approved therapies to drive future upside. Current share weakness may present a buying opportunity given VOXZOGO's prospects.
SG Americas Securities LLC Acquires 36,938 Shares of Amicus Therapeutics, Inc. $FOLD
SG Americas Securities LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 53.2% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 106,358 shares of the biopharmaceutical company's stock after buying an additional 36,938 shares during the
Capricorn Fund Managers Ltd Invests $3 Million in Amicus Therapeutics, Inc. $FOLD
Capricorn Fund Managers Ltd bought a new stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 210,674 shares of the biopharmaceutical company's stock, valued at approximately $3,000,000. Capricorn Fund Managers Ltd
Leading Financial Trade Associations, Led by LSTA, Submit Amicus Brief in Support of Defendant Lenders in Antitrust Case Filed by Optumum Communications
NEW YORK--(BUSINESS WIRE)--LSTA, the trade association for the U.S. corporate lending market, today was joined by SIFMA, the MFA, the Investment Company Institute and the Creditor Rights Coalition, in submitting an amicus brief in support of the defendant lenders in a misguided antitrust case filed by Optimum Communications, Inc. The complaint, one of the first of its kind, is an attempt to apply traditional antitrust principles to “Cooperation Agreements”, which have grown increasingly common.
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD
Avoro Capital Advisors LLC reduced its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 16.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,025,000 shares of the biopharmaceutical company's stock after selling 2,975,000 shares during the period.
Microsoft files amicus brief in support of Anthropic's lawsuit with US DOD
Microsoft filed on Tuesday a proposed brief in support of Anthropic's lawsuit asking the court to temporarily block the U.S. Department of Defense's designation of the AI startup as a supply-chain risk.
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues
FOLD's Q4 earnings miss, but revenues beat estimates on strong Galafold and Pombiliti sales. The company is set to be acquired by BioMarin for $4.8 billion.
Amicus Therapeutics, Inc. $FOLD Shares Sold by Granite Investment Partners LLC
Granite Investment Partners LLC cut its stake in Amicus Therapeutics, Inc. (NASDAQ: FOLD) by 2.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,118,696 shares of the biopharmaceutical company's stock after selling 42,506 shares during the period. Amicus
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates
2025 Total Revenue of $634M, up 17% Year-over-Year at CER Cash Position of $294M, a $44M Increase in 2025 Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases, today announced financial results for the full year ended December 31, 2025.
What to Expect From These Drug/Biotech Players This Earnings Season?
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings?
FOLD heads into Q4 earnings with Galafold driving growth and Pombiliti + Opfolda aiding the top line. BioMarin is set to acquire the company for $4.8 billion.
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold® (migalastat) in Fabry disease and POMBILITI® + OPFOLDA® (cipaglucosidase alfa plus miglustat) in late-onset Pompe disease.
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?
Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock
Amicus Therapeutics, Inc. (NASDAQ: FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of the company's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the completion of the transaction, the chief executive officer owned 1,021,180 shares in
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus shareholders. Halper Sadeh encourages Amicus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Amicu.
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More
Pre-Market Stock Futures: The futures are trading higher this morning, following a solid bounce-back rally across the major indices on Wednesday, after the worst day for stocks since October. Stocks were headed lower at the open, but as President Trump addressed the audience at the World Economic Forum in Davos, Switzerland, the moment he mentioned... Here Are Thursday's Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More.
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock?
Amicus stock soars 135.8% in six months as demand for marketed products grows. The company is set to be acquired by BioMarin for $4.8 billion.
Price Targets
Jefferies Downgrades Amicus Therapeutics (FOLD) to Hold
$14.50
(was $14.35)
Dennis Ding
·
Jefferies
Amicus downgraded to Neutral from Overweight at Cantor Fitzgerald
$14.50
(was $14.25)
Cantor Fitzgerald
Needham upgrades Amicus to Buy on reduced regulatory risk
$14.00
(was $8.31)
Needham
Amicus Therapeutics (FOLD) PT Raised to $15 at BofA Securities
$15.00
(was $12.03)
Tazeen Ahmad
·
Bank of America Securities
Amicus upgraded to Buy from Neutral at Guggenheim
$13.00
(was $9.04)
Debjit Chattopadhyay
·
Guggenheim
Amicus Therapeutics (FOLD) PT Lowered to $19 at Morgan Stanley
$19.00
(was $9.48)
Jeffrey Hung
·
Morgan Stanley
Morgan Stanley Upgrades Amicus Therapeutics (FOLD) to Overweight
$20.00
(was $12.66)
Jeffrey Hung
·
Morgan Stanley
Amicus Therapeutics (FOLD) PT Lowered to $14 at Goldman Sachs
$14.00
(was $9.39)
Salveen Richter
·
Goldman Sachs